Dermata Therapeutics, Inc.
DRMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $504 | $618 | $1,281 | $2,192 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,256 | $1,155 | $1,059 | $1,008 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,761 | $1,773 | $2,340 | $3,200 |
| Operating Income | -$1,761 | -$1,773 | -$2,340 | -$3,200 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $69 | $72 | $36 | $49 |
| Pre-Tax Income | -$1,692 | -$1,701 | -$2,304 | -$3,151 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,692 | -$1,701 | -$2,304 | -$3,151 |
| % Margin | – | – | – | – |
| EPS | -1.65 | -1.66 | -4.47 | -20.4 |
| % Growth | 0.6% | 62.9% | 78.1% | – |
| EPS Diluted | -1.65 | -1.66 | -4.47 | -20.4 |
| Weighted Avg Shares Out | 1,026 | 1,027 | 516 | 156 |
| Weighted Avg Shares Out Dil | 1,026 | 1,027 | 516 | 156 |
| Supplemental Information | – | – | – | – |
| Interest Income | $69 | $72 | $36 | $49 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1,692 | -$1,701 | -$2,304 | -$3,151 |
| % Margin | – | – | – | – |